AXSOME THERAPEUTICS, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
AXSOME THERAPEUTICS, INC. (AXSM) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $3.21 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-10
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $3.21M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $4.80M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.61M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $3.21M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $3.21M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $4.80M 10-Q · filed 2026-05-04 |
| 2025-09-30 | $1.61M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $3.21M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $4.80M 10-Q · filed 2025-05-05 |
| 2024-09-30 | $1.61M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $3.21M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $4.80M 10-Q · filed 2024-05-06 |
| 2023-09-30 | $1.61M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $3.21M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $6.38M 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |